Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in
which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular …

Background Genetic mutations drive the pathogenesis of the myelodysplastic syndrome
(MDS) and are closely associated with clinical phenotype. Therefore, genetic mutations may …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …

The heterogeneous nature of myelodysplastic syndromes (MDS) demands a complex and
personalized variety of therapeutic approaches. Among them, allogeneic hematopoietic …

Importance Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic
syndromes, are clonal hematopoietic malignancies that cause morphologic bone marrow …

Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …

Genetic alterations, including mutations and copy-number alterations, are central to the
pathogenesis of myelodysplastic syndromes and related diseases (myelodysplasia), but …